Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin |
| |
Authors: | Smallshaw Joan E Richardson James A Pincus Seth Schindler John Vitetta Ellen S |
| |
Affiliation: | The Cancer Immunobiology Center, UT Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, NB9.210, Dallas, TX 75390-8576, USA. |
| |
Abstract: | Ricin toxin is a plant-derived ribosome inactivating protein (RIP) of extraordinary toxicity. Vaccination using ricin toxoid or its A chain (RTA) is protective in animals but both vaccines have two potential toxicities, RIP and vascular leak syndrome (VLS). Previously we described three recombinant RTA constructs from which both toxicities were eliminated by site-specific mutations. One mutant, V76M/Y80A, RiVax, has now been further characterized for immunogenicity and toxicity in animals. We have found that RiVax is safe at doses of at least 8 mg in mice, 800-fold higher than the protective dose, and induces neutralizing antibodies in both mice and rabbits. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|